ArticleGeroScience2026
Prioritizing clinical utility to use allostatic load as a biomarker of the consequences of stress.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Allostatic load measures the physiological consequences of stress and is associated with disease outcomes. Clinical use of allostatic load is limited, in part, because its calculation requires biomarkers not routinely measured in clinical care. Presently, we evaluated associations between high allostatic load and depression as co-occurring consequences of stress among a cohort representing population subgroups largely excluded from existing literature. We emphasize clinical implementation potential by employing both an established and a recent consensus streamlined allostatic load score. Data arise from a nested case-control study within the Southern Community Cohort Study (N = 982); 72% self-identified as Black, 61% reported income < $15,000. At baseline, participants completed surveys and provided blood samples analyzed for immune, metabolic, and cardiovascular biomarkers. Biomarkers exceeding clinical cutoffs were summed; counts above median indicated high allostatic load. Established and streamlined scores include 10 (albumin, C-reactive protein, estimated creatinine clearance, BMI, HbA1C, homocysteine, systolic and diastolic blood pressure, total cholesterol, triglycerides) and a subset of 5 biomarkers, respectively. Logistic regression models assessed cross-sectional associations between depression and allostatic load at study entry (odds ratios [OR], 95% confidence intervals [CI]). Established and streamlined scores demonstrated 88% agreement in identifying high allostatic load. Depression was associated with high allostatic load using both scores (established: OR: 1.37, 95%CI: 1.02-1.86; streamlined: OR: 1.39, 95%CI: 1.03-1.87). Associations remained in sex, race, and CRC-status stratified analyses. Robust associations were observed between depression, as a proxy measure of stress, with high allostatic load, supporting its validity as a clinically actionable biomarker of physiological and psychological dysregulation within an understudied population. Implementing the streamlined score may increase feasibility of allostatic load as a clinical indicator of stress.
Indexed as
Identifiers
42563072What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.